Provided by Tiger Fintech (Singapore) Pte. Ltd.

Y-mAbs Therapeutics, Inc.

4.13
+0.01000.24%
Volume:216.55K
Turnover:877.06K
Market Cap:186.75M
PE:-6.16
High:4.14
Open:3.99
Low:3.91
Close:4.12
Loading ...

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) latest 12% decline adds to one-year losses, institutional investors may consider drastic measures

Simply Wall St.
·
03 Apr

Bearish: Analysts Just Cut Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Revenue and EPS estimates

Simply Wall St.
·
09 Mar

Y-Mabs Therapeutics (YMAB) Gets a Buy from Oppenheimer

TIPRANKS
·
05 Mar

Y-mAbs Therapeutics Inc : Truist Securities Cuts Target Price to $18 From $21

THOMSON REUTERS
·
05 Mar

Y-mAbs Therapeutics Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.
·
05 Mar

Y-mAbs Therapeutics Inc (YMAB) Q4 2024 Earnings Call Highlights: Strategic Realignment and ...

GuruFocus.com
·
05 Mar

Q4 2024 Y-mAbs Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
05 Mar

BRIEF-Y-mAbs Therapeutics Inc Enters Equity Distribution Agreement With Oppenheimer

Reuters
·
05 Mar

Y-mAbs Therapeutics Inc - Enters Equity Distribution Agreement With Oppenheimer

THOMSON REUTERS
·
05 Mar

Y-mAbs Therapeutics Inc - to Sell Common Stock up to $35 Million

THOMSON REUTERS
·
05 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Okta, Natgas companies, UnitedHealth

Reuters
·
05 Mar

Wedbush Cuts Price Target on Y-mAbs Therapeutics to $21 From $23, Keeps Outperform Rating

MT Newswires Live
·
05 Mar

BUZZ-Y-mAbs Therapeutics falls following gloomy 2025 revenue forecast

Reuters
·
05 Mar

Y-mAbs Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
04 Mar

Y-mAbs Therapeutics (NASDAQ:YMAB) shareholders have endured a 79% loss from investing in the stock five years ago

Simply Wall St.
·
04 Mar

Y-mAbs Shares Fall After Outlook, 4Q Revenue Miss

Dow Jones
·
04 Mar

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Lags Revenue Estimates

Zacks
·
04 Mar

BRIEF-Y-mAbs Reports Fourth Quarter 2024 Financial Results

Reuters
·
04 Mar

Y-mAbs Revenue Outlook: For 2025 Expected Between $75M - $90M Vs. $104.537M Est.; For Q1, Expected Between $18M - $21M Vs. $24.37M Est.

Benzinga
·
04 Mar

Y-mAbs Therapeutics Inc: Qtrly Loss per Share $0.15

THOMSON REUTERS
·
04 Mar